文献速递瓣膜外科

风湿性二尖瓣手术:瓣中瓣时代修复与置换的策略选择

Rheumatic mitral valve repair or replacement in the valve-in-valve era.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-05-11

该研究回顾性分析了180例首次孤立风湿性二尖瓣手术患者,比较两个年代(1997-2008与2009-2018)以术中前叶活动度/钙化评估决定修复或置换的策略差异。结果显示第二年代复合终点(死亡、再手术、严重瓣膜功能障碍)5年无事件率更高(72%±9% vs 54%±13%,P=.04),但再手术累积发生率修复高于置换。

要点

  • 以术中前叶活动度/钙化评估决定修复或置换与更优复合结局相关。
  • 第二年代修复比例更低(33% vs 70%,P<.001),5年无事件率更高。
  • 再手术累积发生率修复高于置换,但两组5年生存无差异。

核心结论

  • 以术中前叶活动度/钙化评估指导风湿性二尖瓣修复或置换的决策策略与复合结局改善相关。
  • 该策略可能改变当前瓣中瓣时代风湿性二尖瓣置换的阈值。

研究设计与样本

  • 回顾性队列研究,纳入180例首次孤立风湿性二尖瓣手术患者。
  • 按年代分为第一年代(1997-2008,n=56)与第二年代(2009-2018,n=124),后者以术中前叶活动度/钙化评估决定修复或置换。
  • 主要终点为死亡、再手术和严重瓣膜功能障碍的复合终点。

主要发现

  • 患者年龄59±14岁,射血分数58%±10%。
  • 第一年代术前房颤比例高于第二年代(68% vs 46%;P=.006)。
  • 主要指征为二尖瓣狭窄者占69%(124/180;单纯35例,混合89例),两年代无差异(P=.67)。
  • 第一年代修复占70%(39/56),第二年代修复占33%(41/124)(P<.001)。
  • 5年无死亡、再手术或严重瓣膜功能障碍率第二年代为72%±9%,高于第一年代的54%±13%(P=.04)。

临床怎么用

  • 对风湿性二尖瓣病变,术中评估前叶活动度与钙化有助于决定修复或置换。
  • 在瓣中瓣时代,该评估策略可能影响风湿性二尖瓣置换的选择阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: For degenerative mitral disease, repair is superior to replacement; however, the best operative strategy for rheumatic mitral disease remains unclear. We evaluated the association between decision-making in choosing repair versus replacement and outcomes across 2 decades of rheumatic mitral surgery. METHODS: Patients undergoing isolated, first-time rheumatic mitral surgery were identified. Era 1 (1997-2008) and Era 2 (2009-2018) were distinguished by intraoperative assessment of anterior leaflet mobility/calcification (Era 2) in deciding between mitral repair versus replacement. Primary outcome was a composite of death, reoperation, and severe valve dysfunction. RESULTS: Among 180 patients, age was 59 ± 14 years, and ejection fraction was 58% ± 10%. A higher proportion in Era 1 (n = 56) compared with Era 2 (n = 124) had preoperative atrial fibrillation (68% vs 46%; P = .006); the groups were otherwise similar. Primary indication was mitral stenosis in 69% (124 out of 180; pure = 35, mixed = 89) and did not differ by era (P = .67). During Era 1, 70% (39 out of 56) underwent repair, compared with 33% (41 out of 124) during Era 2 (P < .001). Freedom from death, reoperation, or severe valve dysfunction at 5 years was higher in Era 2 (72% ± 9%) than Era 1 (54% ± 13%; P = .04). Five-year survival was higher in Era 2 than Era 1, but did not differ between repair versus replacement. Five-year cumulative incidence of reoperation with death as a competing risk did not differ by era, but was higher after repair than replacement. CONCLUSIONS: Careful assessment of anterior leaflet mobility/calcification to determine mitral repair or replacement was associated with improved outcomes. This decision-making strategy may alter the threshold for rheumatic mitral replacement in the current valve-in-valve era.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Brescia AA, Watt TMF, Murray SL, et al. Rheumatic mitral valve repair or replacement in the valve-in-valve era. J Thorac Cardiovasc Surg. 2020. PMID: 32620398. doi:10.1016/j.jtcvs.2020.04.118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。